Trial Condition(s):

Atherosclerosis

Study to gain insights in treatment patterns and outcomes in patients with atherosclerosis prescribed to Xarelto in combination with acetylsalicylic acid (XATOA)

Bayer Identifier:

20280

ClinicalTrials.gov Identifier:

NCT03746275

EudraCT Number:

Not Available

Study Completed

Trial Purpose

In this study researchers want to gain more information on treatment patterns of patients treated with Xarelto in combination with acetylsalicylic acid (ASA). Both drugs reduce the risk of blood clots via different pathways. The study will enroll adult patients suffering from coronary artery disease (narrowing or blockage of vessels that supply the heart with blood) or peripheral artery disease (narrowing or blockage of vessels that supply the legs or head with blood). The study will focus on information on when and why physicians are starting to treat patients with Xarelto in addition to ASA, treatment duration, reasons to discontinue treatment and previous therapies. The study will also look into treatment outcomes for patients being treated with a combination of Xarelto and ASA by their physicians.

Inclusion Criteria
- Adults with diagnosis Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD).
                - Treatment according to local marketing authorization, rivaroxaban 2.5 mg twice daily started within 4 weeks prior to enrolment. Only in those countries with a marketing authorization of rivaroxaban in the acute coronary syndrome (ACS) indication, also patients already on rivaroxaban treatment for ACS, who are subsequently fulfilling criteria for CAD, are allowed to be enrolled within 4 weeks of this decision being made.
Exclusion Criteria
- Patients who will be treated with chronic anticoagulation therapy other than rivaroxaban 2.5 mg given for CAD/PAD.
                - Participation in an interventional trial.

Trial Summary

Enrollment Goal
5798
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)+ASA
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Multiple facilities

Many locations, Germany

Status
Completed
 
Locations

Multiple facilities

Many locations, United Kingdom

Status
Completed
 
Locations

Multiple facilities

Many locations, Canada

Status
Completed
 
Locations

Multiple facilities

Many locations, Mexico

Status
Completed
 
Locations

Multiple facilities

Many locations, Sweden

Status
Completed
 
Locations

Multiple facilities

Many locations, Denmark

Status
Completed
 
Locations

Multiple facilities

Many locations, Norway

Status
Completed
 
Locations

Multiple facilities

Many locations, Israel

Status
Completed
 
Locations

Multiple facilities

Many locations, Argentina

Status
Completed
 
Locations

Multiple facilities

Many locations, Brazil

Status
Completed
 
Locations

Multiple facilities

Many locations, Russia

Status
Completed
 
Locations

Multiple facilities

Many locations, South Korea

Status
Completed
 
Locations

Multiple facilities

Many locations, Thailand

Status
Completed
 
Locations

Multiple facilities

Many locations, Luxembourg

Status
Completed
 
Locations

Multiple facilities

Many locations, Switzerland

Status
Completed
 
Locations

Multiple facilities

Many locations, Lebanon

Status
Completed
 
Locations

Multiple facilities

Many locations, United Arab Emirates

Status
Completed
 
Locations

Multiple facilities

Many locations, Slovenia

Status
Completed
 

Trial Design